C4 Therapeutics, Inc. (CCCC) Stock Price

CCCCStock

$3.85+50.98%52W

Market Cap$473.65M

P/E—

PEG Ratio—

Div yield—

Beta3.07

CCCC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)49.16%

Price vs S&P 500 (4W)8.46%

VGM Score45.43

Book Value / Share (Quarterly)$2.25

P/TBV (Annual)0.26x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)4.95%

Cash Flow / Share (Quarterly)$-0.92

Price vs S&P 500 (YTD)88.75%

Net Profit Margin (TTM)-297.76%

EPS (TTM)$-1.18

10-Day Avg Trading Volume2.30M

EPS Excl Extra (TTM)$-1.18

Revenue Growth (5Y)1.60%

EPS (Annual)$-1.27

ROI (Annual)-40.92%

Net Profit Margin (5Y Avg)-364.35%

Cash / Share (Quarterly)$2.27

Revenue Growth QoQ (YoY)-15.00%

ROA (Last FY)-29.24%

Revenue Growth TTM (YoY)-12.37%

EBITD / Share (TTM)$-1.16

ROE (5Y Avg)-41.87%

Operating Margin (TTM)-326.56%

Cash Flow / Share (Annual)$-1.02

P/B Ratio2.12x

P/B Ratio (Quarterly)1.10x

Net Income / Employee (Annual)$-1,009,600

EV / Revenue (TTM)12.52x

Net Interest Coverage (TTM)-46.66x

ROA (TTM)-33.22%

EPS Incl Extra (Annual)$-1.27

Current Ratio (Annual)7.81x

Quick Ratio (Quarterly)8.75x

3-Month Avg Trading Volume2.95M

52-Week Price Return50.98%

Revenue / Employee (TTM)$335,200

Tangible BV / Share (Quarterly)$4.39

P/S Ratio (Annual)13.84x

Asset Turnover (Annual)0.10x

52-Week High$5.17

Operating Margin (5Y Avg)-385.07%

EPS Excl Extra (Annual)$-1.27

CapEx CAGR (5Y)-1.36%

26-Week Price Return61.09%

Quick Ratio (Annual)7.60x

13-Week Price Return5.19%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.00x

Enterprise Value$436.36M

Revenue / Share Growth (5Y)-10.87%

Asset Turnover (TTM)0.11x

Book Value / Share Growth (5Y)-16.48%

Revenue / Employee (Annual)$345,600

Pretax Margin (Annual)-291.74%

Cash / Share (Annual)$2.56

3-Month Return Std Dev73.52%

Net Income / Employee (TTM)$-998,100

ROE (Last FY)-40.92%

Net Interest Coverage (Annual)-88.52x

EPS Basic Excl Extra (Annual)$-1.27

Receivables Turnover (TTM)6.39x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.18

Receivables Turnover (Annual)13.06x

ROI (TTM)-50.68%

P/S Ratio (TTM)14.27x

Pretax Margin (5Y Avg)-362.97%

Revenue / Share (Annual)$0.43

Tangible BV / Share (Annual)$5.91

Price vs S&P 500 (52W)32.42%

Year-to-Date Return101.57%

5-Day Price Return-6.10%

EPS Normalized (Annual)$-1.27

ROA (5Y Avg)-28.17%

Net Profit Margin (Annual)-292.08%

Month-to-Date Return10.63%

Cash Flow / Share (TTM)$-2.71

EBITD / Share (Annual)$-1.37

Operating Margin (Annual)-320.53%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-41.42%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.18

P/TBV (Quarterly)0.35x

P/B Ratio (Annual)0.72x

Pretax Margin (TTM)-297.41%

Book Value / Share (Annual)$2.65

Price vs S&P 500 (13W)3.24%

Beta3.07x

P/FCF (Annual)9.17x

Revenue / Share (TTM)$0.28

ROE (TTM)-50.68%

52-Week Low$1.69

vGradeC

gGradeD

mGradeB

vgmGradeC

CCCC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	-$0.23	-$0.18	+21.74%(+$0.05)
Q1 2026	May 12, 2026	-$0.26	-$0.20	+23.08%(+$0.06)
Q4 2025	Feb 26, 2026	-$0.39	-$0.18	+54.24%(+$0.21)
Q3 2025	Nov 6, 2025	-$0.41	-$0.44	-7.68%(-$0.03)
Q2 2025	Aug 7, 2025	-$0.38	-$0.37	+3.27%(+$0.01)

CCCC Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.29

4.23

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
CCCCC4 Therapeutics, Inc.	C	D	B	$3.85
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About C4 Therapeutics, Inc.

C4 Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies designed to address difficult-to-treat cancers and other diseases. Its proprietary TORPEDO platform enables the efficient design of small-molecule degraders that leverage the body's natural protein recycling system to overcome drug resistance and tackle undruggable targets. The company's pipeline includes three oncology programs: Cemsidomide, CFT1946, and CFT8919.